[1]郎海雷,曹雷涛,贵英斌,等.LncRNA NNT-AS1 通过调控miR-582-5p/NCKAP1 轴激活Hippo-YAP/TAZ 信号通路促进膀胱癌细胞增殖、迁移、侵袭和干细胞干性影响[J].现代检验医学杂志,2023,38(04):27-34+39.[doi:10.3969/j.issn.1671-7414.2023.04.005]
　LANG Hailei,CAO Leitao,GUI Yingbin,et al.LncRNA NNT-AS1 Activates Hippo-YAP/TAZ Signaling Pathway by Regulating miR-582-5p/NCKAP1 Axis to Promote Bladder Cancer Cell Proliferation, Migration, Invasion and Stem Cell Stemness Effects[J].Journal of Modern Laboratory Medicine,2023,38(04):27-34+39.[doi:10.3969/j.issn.1671-7414.2023.04.005]
点击复制

LncRNA NNT-AS1 通过调控miR-582-5p/NCKAP1 轴激活Hippo-YAP/TAZ 信号通路促进膀胱癌细胞增殖、迁移、侵袭和干细胞干性影响()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年04期
页码:
27-34+39
栏目:
论著
出版日期:
2023-07-15

文章信息/Info

Title:
LncRNA NNT-AS1 Activates Hippo-YAP/TAZ Signaling Pathway by Regulating miR-582-5p/NCKAP1 Axis to Promote Bladder Cancer Cell Proliferation, Migration, Invasion and Stem Cell Stemness Effects
文章编号:
1671-7414（2023）04-028-08
作者:
郎海雷; 曹雷涛; 贵英斌; 张天禹
（定州市人民医院，河北定州 073000）
Author(s):
LANG Hailei;  CAO Leitao;  GUI Yingbin;  ZHANG Tianyu
（Dingzhou People’s Hospital, Hebei Dingzhou 073000, China）
关键词:
膀胱癌; 长链非编码核糖核酸烟酰胺核苷酸转氢酶反义RNA 1; miR-582-5p/NCKAP1;  Hippo-YAP/TAZ 通路;  增殖; 迁移; 侵袭; 肿瘤干细胞干性
分类号:
R737.14；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.04.005
文献标志码:
A
摘要:
目的　检测膀胱癌中长链非编码 RNA（long non-coding RNA, lncRNA）烟酰胺核苷酸转氢酶反义RNA1（nicotinamide nucleotide transhydrogenase antisense RNA 1, NNT-AS1）表达情况，研究其对膀胱癌细胞增殖、迁移、侵袭及肿瘤干细胞干性的影响及可能分子机制。方法　实时荧光定量PCR（quantitative real-time PCR，qRT-PCR）法检测膀胱癌组织标本及细胞中LncRNA NNT-AS1 表达情况；将膀胱癌细胞转染分为sh-NC 组，sh-NNT-AS1 组，sh-NNTAS1+inh-582-5p 组和sh-NNT-AS1+inh-582-5p+si-NCKAP1 组。采用CCK-8 法检测细胞增殖吸光度值（A 值）；Transwell实验检测细胞迁移、侵袭穿膜数；细胞成球实验检测干细胞干性。检索starBase 和TargetScan 数据库，并通过双荧光素酶报告基因实验预测验证LncRNA NNT-AS1 和miR-582-5p，miR-582-5p 与NCKAP1 的靶向结合关系。Western blot 检测膀胱癌干细胞标志蛋白(CD44，ALDH1A1，Oct4，Nanog) 及Hippo-YAP/TAZ 信号通路相关蛋白表达灰度值。结果　与癌旁组织相比，膀胱癌组织中LncRNA NNT-AS1 表达水平（0.34±0.07 vs 1.15±0.21）明显升高，差异有统计学意义（t=16.364，P ＜ 0.001）。与人正常膀胱上皮SV-HUC-1 细胞（1.00±0.01）相比，膀胱癌细胞T24，5637，UM-UC-3和TCC-SUP 中LncRNA NNT-AS1 表达（6.03±0.17，4.66±0.36，5.47±0.26，3.02±0.20）明显升高，差异有统计学意义（t=17.472~51.160，均P ＜ 0.001）。与sh-NC 组相比，在24，48 和72 h 时sh-NNT-AS1 组细胞增值能力（A 值）均显著降低（0.80±0.01 vs 1.07±0.06，1.18±0..07 vs 1.83±0.03，1.89±0.07 vs 2.53±0.06），差异有统计学意义（t=7.688,14.783，12.024，均P ＜ 0.05）；sh-NNT-AS1 组细胞迁移穿膜数（55.00±2.65 个 vs 354.30±7.84 个）、细胞侵袭穿膜数（45.67±2.33 个 vs 303.00±9.07 个）及膀胱癌干细胞成球数（20.85±2.17 个 vs 41.35±3.67 个）显著降低，差异具有统计学意义（t=-62.641，-47.596，8.328，均P ＜ 0.001）。与sh-NC 组相比，sh-NNT-AS1 组细胞中CD44（0.04±0.01vs 1.12±0.02），ALDH1A1（0.23±0.01 vs 1.16±0.05），Oct4（0.17±0.02 vs 1.10±0.04），Nanog（0.49±0.03 vs 1.24±0.03）的蛋白表达灰度值显著降低，差异具有统计学意义（t=83.656，31.591，36.019，30.619，均P ＜ 0.001）。与si-NC 组相比，sh-NNT-AS1 组CD44+CD133+ 细胞比例（9.30%±0.79% vs 88.50%±2.77%）明显降低，差异有统计学意义（t=-47.624，P ＜ 0.001）。双荧光素酶报告基因检测结果显示miR-582-5p 为LncRNA NNT-AS1 靶基因，NCKAP1为miR-582-5p 靶基因；LncRNA NNT-AS1 靶向调控miR-582-5p/NCKAP1 轴。与sh-NNT-AS1 组相比， 在24，48，72 h 时sh-NNT-AS1+inh-582-5p 组细胞增值能力（A值）均明显升高（0.98±0.03 vs 0.73±0.06，1.74±0.04 vs 1.22±0.05，2.33±0.16 vs 1.69±0.14），差异有统计学意义（t=5.977~11.628，均P ＜ 0.001）。与sh-NNT-AS1+inh-582-5p 组相比，在24，48，72 h 时sh-NNTAS1+inh-582-5p+si-NCKAP1 组细胞增值能力（A 值）显著降低（0.69±0.04，1.01±0.07，1.39±0.08），差异有统计学意义（t=7.877~16.323，均P ＜ 0.001）。与sh-NNT-AS1 组相比，sh-NNT-AS1+inh-582-5p 组细胞迁移穿膜数（322.31±28.45个 vs 81.42±13.22 个）、细胞侵袭穿膜数（316.07±30.21 个 vs 92.13±12.65 个）及膀胱癌干细胞成球数（38.55±2.20个 vs 18.98±1.16 个）显著增加，差异具有统计学意义（t=15.115，13.158，14.592，均P ＜ 0.001）。与sh-NNT-AS1组相比，sh-NNT-AS1+inh-582-5p 组细胞CD44（1.05±0.08 vs 0.10±0.01），ALDH1A1（1.20±0.16 vs 0. 22±0.02），Oct4（1.32±0.14 vs 0.19±0.03），Nanog（0.97±0.12 vs 0.15±0.04），YAP（1.29±0.11 vs 0.42±0.07）和TAZ（1.41±0.16vs 0.35±0.05）蛋白表达灰度值均显著增加，差异具有统计学意义（t=10.650~21.243，均P ＜ 0.001）。与sh-NNTAS1+inh-582-5p 组相比，sh-NNT-AS1+inh-582-5p+si-NCKAP1 组细胞迁移穿膜数（65.33±12.60 个）、细胞侵袭穿膜数（71.08±15.19 个）、膀胱癌干细胞成球数（11.36±1.05 个）均显著降低，差异具有统计学意义（t=16.125，14.395，21.365，均P＜ 0.001）。与sh-NNT-AS1+inh-582-5p 组相比，sh-NNT-AS1+inh-582-5p+si-NCKAP1 组细胞CD44（0.25±0.05），ALDH1A1（0.61±0.11），Oct4（0.22±0.08），Nanog（0.44±0.07），YAP（0.25±0.09）和TAZ（0.30±0.04）蛋白表达灰度值显著降低，差异具有统计学意义（t=6.412~17.889，均P ＜ 0.001）。结论　膀胱癌中LncRNA NNT-AS1 表达上调，其对膀胱癌细胞增殖、侵袭及肿瘤干细胞干性的影响，可能是通过调控miR-582-5p/NCKAP1 分子轴，激活Hippo-YAP/TAZ 信号通路完成。
Abstract:
Objective　To detect the expression of long non coding RNA (LncRNA) nicotinamide nucleotide transhydrogenase antisense RNA1 (NT-AS1) in bladder cancer, and investigate its effect on the proliferation, migration and invasion of bladder cancer cells and the stemness of tumor stem cells and its possible molecular mechanism. Methods　LncRNA NNT-AS1 expression in bladder cancer tissues and cells was detected by quantitative real-time PCR (qRT-PCR). Bladder cancer cells were transfected into sh-NC group, sh-NNT-AS1 group, sh-NNT-AS1+inh-582-5p group and sh-NNT-AS1+inh-582-5p+si- NCKAP1 group. Cell proliferation absorbance (A value) was detected by CCK-8 method. Transwell assay was used to detect cell migration and invasion through membrane. The number of cell pellet formation was measured by tumor stem cell pellet formation assay.The starBase and TargetScan databases were searched, and the targeted binding relationship between LncRNA NNT-AS1 and miR-582-5p, miR-582-5p and NCKAP1 was predicted and verified by double luciferase reporter gene experiment. Western blot analysis was performed to detect the expression gray values of marker proteins (CD44, ALDH1A1, Oct4, Nanog) and Hippo-YAP /TAZ signaling pathways. Results　LncRNA NNT-AS1 expression in bladder cancer tissues was significantly higher than that in adjacent tissues (0.34±0.07 vs 1.15±0.21), and the difference was statistically significant (t=16.364, P ＜ 0.001). LncRNA NNT-AS1 expression in bladder cancer cells T24, 5637, UM-UC-3 and TCC-SUP(6.03±0.17, 4.66±0.36, 5.47±0.26, 3.02±0.20) were significantly higher than that in normal human bladder epithelial SV-HUC-1 cells(1.00±0.01), and the differences were statistically significant (t=17.472~51.160, all P ＜ 0.001). Compared with sh-NC group, cell A value in sh- NNT-AS1 group(0.80±0.01 vs 1.07±0.06, 1.18±0.07 vs 1.83±0.03, 1.89±0.07 vs 2.53±0.06) was significantly decreased at 24, 48 and 72 h, and the differences were statistically significant (t=7.688, 14.783, 12.024, all P ＜ 0.05). Compared with sh- NC group, the number of cell migration through the membrane (55.00±2.65 vs 354.30±7.84), the number of cell invasions through the membrane (45.67±2.33 vs 303.00±9.07), and the number of bladder cancer stem cells bulging (20.85±2.17 vs 41.35±3.67) were significantly reduced in sh-NNT-AS1 group (t=-62.641, -47.596, 8.328, all P ＜ 0.001). Compared with sh-NC group, the expression gray values of CD44(0.04±0.01 vs 1.12±0.02), ALDH1A1(0.23±0.01 vs 1.16±0.05), Oct4(0.17±0.02 vs 1.10±0.04) and Nanog(0.49±0.03 vs 1.24±0.03) protein in sh-NNT-AS1 group were significantly decreased, and the differences were statistically significant (t=83.656, 31.591, 36.019, 30.619, all P ＜ 0.001). Compared with si-NC group, the proportion of CD44+CD133+ cells in sh-NNT-AS1 group was significantly decreased (9.30%±0.79% vs 88.50%±2.77%), and the difference was statistically significant (t=-47.624, P ＜ 0.001). The results of double luciferase reporter gene detection showed that miR-582-5p was the target gene of LncRNA NNT-AS1, and NCKAP1 was the target gene of miR-582-5p. LncRNA NNT-AS1 targets miR-582-5p/NCKAP1 axis. Compared with sh-NNT-AS1 group, cell A value in sh- NNT-AS1+inh-582-5p group(0.98±0.03 vs 0.73±0.06, 1.74±0.04 vs 1.22±0.05, 2.33±0.16 vs 1.69±0.14) was significantly increased at 24, 48 and 72 h, and the differences were statistically significant (t=5.977~11.628, all P < 0.001). Compared with sh- NNT-AS1+inh-582-5p group, cell A value in sh-NNT-AS1+inh-582-5p+si-NCKAP1 group(0.69±0.04, 1.01±0.07, 1.39±0.08) was significantly decreased at 24, 48 and 72h, and the differences were statistically significant (t=7.877~16.323, all P ＜ 0.001). Compared with the sh-NNT-AS1 group, the number of cell migration through the membrane (322.31±28.45 vs 81.42±13.22), the number of cell invasion through the membrane (316.07±30.21 vs 92.13±12.65), and the number of bladder cancer stem cells forming balls (38.55±2.20 vs 18.98±1.16) in the sh-NNT-AS1+inh-582-5p group were significantly increased (t=15.115, 13.158, 14.592, P ＜ 0.001).Compared with sh-NNT-AS1 group, the expression gray values of CD44 (1.05±0.08 vs 0.10±0.01), ALDH1A1 (1.20±0.16 vs 0.22±0.02), Oct4 (1.32±0.14 vs 0.19±0.03), Nanog (0.97±0.12 vs 0.15±0.04), YAP (1.29±0.11 vs 0.42±0.07) and TAZ (1.41±0.16 vs 0.35±0.05) protein in sh-NN-T-AS1+inh-582-5p group were significantly increased, and the differences were statistically significant (t=10.650~21.243, all P<0.001).Compared with the sh-NNT-AS1+inh-582-5p group, the number of cell migration through the membrane (65.33±12.60), the number of cell invasion through the membrane (71.08±15.19), and bladder cancer stem cell spherulation number (11.36±1.05) of the sh-NNT-AS1+inh-582-5p+si-NCKAP1 group were significantly reduced (t=16.125, 14.395, 21.365, all P ＜ 0.001).Compared with sh-NNT-AS1+inh-582-5p group, the expression gray values of CD44 (0.25±0.05 ), ALDH1A1 (0.61±0.11), Oct4 (0.22±0.08), Nanog (0.44±0.07), YAP (0.25±0.09) and TAZ (0.30±0.04) protein in sh-NNT-AS1+inh-582-5p+si-NCKAP1 group were significantly increased, and the differences were statistically significant(t=6.412~17.889, all P ＜ 0.001).Conclusion　The expression of LncRNA NNT-AS1 was up-regulated in bladder cancer, and its influence on the proliferation and invasion of bladder cancer cells and the stemness of tumor stem cells may be achieved through the activation of Hippo-YAP/TAZ signaling pathway by regulating the molecular axis of miR-582-5p/NCKAP1.

参考文献/References:

[1] POWLES T, BELLMUNT J, COMPERAT E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J].Ann Oncol, 2022, 33(3):244-258.
[2] SIRACUSANO S, RIZZETTO R, PORCARO A B. Bladder cancer genomics[J]. Urologia, 2020, 87(2):49-56.
[3] BORHANI S, BORHANI R, KAJDACSY-BALLA A. Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction[J]. Crit Rev Oncol Hematol, 2022, 171:103601.
[4] OGUNWOBI O O, MAHMOOD F, AKINGBOYE A. Biomarkers in colorectal cancer: current research and future prospects[J]. Int J Mol Sci, 2020, 21(15):5311.
[5] L? Dezhong, XU Kang, JIN Xiyin, et al. LncSpA:LncRNA spatial atlas of expression across normal and cancer tissues[J]. Cancer Res, 2020, 80(10):2067-2071.
[6] STATELLO L, GUO Chunjie, CHEN Lingling, et al. Gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2):96-118.
[7] LUO Huarong, XU Chengdang, LE Wei, et al. LncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150[1].J Cell Biochem, 2019, 120(8):13487-13493.
[8] ZHUANG Chengle, MA Qian, ZHUANG Changshui, et al. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC[J]. FASEB J, 2019, 33(10):11045-11059.
[9] HUANG J W, LUO X Y, LI Z H, et al. LncRNA NNTAS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis[J]. Eur Rev Med Pharmacol Sci, 2020, 24(1):238-248.
[10] ZHENG Dahai, CHEN Daliang, LIN Famu, et al. LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis[J]. Cell Cycle, 2020, 19(13):1621-1631.
[11] 陈健康, 彭道荣, 陈慧昱, 等. 尿液膀胱肿瘤抗原水平检测在膀胱癌诊断中的意义[J]. 现代检验医学杂志, 2019, 34(6):135-137. CHEN Jiankang, PENG Daorong, CHEN Huiyu, et al.Significance of urine bladder tumor antigen level in the diagnosis of bladder cancer[J].Journal of Modern Laboratory Medicine, 2019, 34(6):135-137.
[12] USUBA W, URABE F, YAMAMOTO Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer[J]. Cancer Sci, 2019, 110(1):408-419.
[13] GUGNONI M, CIARROCCHI A. Long noncoding RNA and epithelial mesenchymal transition in cancer[J]. Int J Mol Sci, 2019, 20(8):1924.
[14] ARAVINDHAN S, YOUNUS L A, HADI LAFTA M, et al. P53 long noncoding RNA regulatory network in cancer development[J]. Cell Biol Int, 2021, 45(8):1583-1598.
[15] WANG Wenhong, LOU Weiyang, DING Bisha, et al. A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer[J]. Aging (Albany NY), 2019, 11(9):2610-2627.
[16] WANG Yunyan, SUN Qing, JI Lu, et al. LncRNA MORT regulates bladder cancer behaviors by downregulating microRNA-146a-5p[J]. Nephron, 2020, 144(7):351-357.
[17] ZHANG Caixiang, WANG Wenying, LIN Jun, et al. LncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion[J]. Int Braz J Urol, 2019, 45(3):549-559.
[18] CAO H L, LIU Z J, HUANG P L, et al. LncRNARMRP promotes proliferation, migration and invasion of bladder cancer via miR-206[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3):1012-1021.
[19] HE Wenlong, ZHANG Yeying, XIA Shulan. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis[J]. Thorac Cancer, 2020, 11(3):549-560.
[20] HUANG Lining, JIANG Xingming, KANG Pengcheng, et al. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma[J]. Cancer Manag Res, 2019, 11:7739-7749.
[21] ZHOU Ruisheng, ZHANG Enxin, SUN Qinfeng, et al. Integrated analysis of LncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue[J]. BMC Cancer, 2019, 19(1):779.
[22] ZHANG Jianfeng, ZHANG Kai, HOU Yingkui. Long non-coding RNA NNT-AS1 knockdown represses the progression of gastric cancer via modulating the miR-142-5p/SOX4/Wnt/β-catenin signaling pathway[J]. Mol Med Rep, 2020, 22(2):687-696.
[23] HUANG J W, LUO X Y, LI Z H, et al. LncRNA NNTAS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis[J]. Eur Rev Med Pharmacol Sci, 2020, 24(1):238-248.
[24] ZHONG Xiaoping, KAN Anna, LING Yihong, et al. NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma[J]. Cell Death Dis, 2019, 10(5):369-381.
[25] CHEN Jiasheng, GE Jianzhang, ZHANG Wancong, et al. NCKAP1 is a Prognostic biomarker for inhibition of cell growth in clear cell renal cell carcinoma[J]. Front Genet, 2022, 13: 764957.
[26] DEY A, VARELAS X, GUAN Kunliang. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine[J]. Nat Rev Drug Discov, 2020, 19(7):480-494.
[27] QIAO Kun, NING Shipeng, WAN Lin, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):418.
[28] WANG Yu, LIU Shuwei. LncRNA GHET1 promotes hypoxia-induced glycolysis, proliferation, and invasion in triple-negative breast cancer through the Hippo/YAP signaling pathway[J]. Front Cell Dev Biol, 2021, 9:643515.
[29] LIN Xueke, FENG Dilu, LI Ping, et al. LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway[J]. Cancer Med, 2020, 9(21):8122-8132.
[30] ZHU Bowen, V M, Finch-Edmondson M, et al. MiR-582-5p is a tumor suppressor microRNA targeting the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer[J]. Cancer, 2021, 13(4):756-775.

相似文献/References:

[1]谢小娟,朱 娜,潘晶晶,等.miRNA-148a在膀胱癌组织中的表达及生物信息学分析[J].现代检验医学杂志,2015,30(04):6.[doi:10.3969/j.issn.1671-7414.2015.04.002]
　XIE Xiao-juan,ZHU Na,PAN Jing-jing,et al.Expression of miRNA-148a in Bladder Carcinoma Tissues and Its Bioinformatics Analysis[J].Journal of Modern Laboratory Medicine,2015,30(04):6.[doi:10.3969/j.issn.1671-7414.2015.04.002]
[2]陈健康,彭道荣,陈慧昱,等.尿液膀胱肿瘤抗原水平检测在膀胱癌诊断中的意义[J].现代检验医学杂志,2019,34(06):135.[doi:10.3969 ／ j.issn.1671-7414.2019.06.034]
　CHEN Jian-kang,PENG Dao-rong,CHEN Hui-yu,et al.Significance of Urine Bladder Tumor Antigen Level in the Diagnosis of Bladder Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):135.[doi:10.3969 ／ j.issn.1671-7414.2019.06.034]
[3]梅 竹,任 赛,唐思恬,等.膀胱癌患者尿液外泌体中miR-494-3p，LncRNA MAGI2-AS3 表达水平及临床价值研究[J].现代检验医学杂志,2024,39(04):5.[doi:10.3969/j.issn.1671-7414.2024.04.002]
　MEI Zhu,REN Sai,TANG Sitian,et al.Study on Expression Levels and Clinical Value of miR-494-3p and LncRNA MAGI2-AS3 in Urine Exosomes of Patients with Bladder Cancer[J].Journal of Modern Laboratory Medicine,2024,39(04):5.[doi:10.3969/j.issn.1671-7414.2024.04.002]

备注/Memo

备注/Memo:
基金项目：2019 年河北省科技计划项目（H2019-0638）：LncRNA NNT-ASI 促进膀胱癌进展和肿瘤干细胞干性的作用机制研究。
作者简介：郎海雷（1982-），男，本科，主治医师，研究方向: 恶性肿瘤，E-mail：weqwss25@163.com，电话：15033728766。
更新日期/Last Update: 2023-07-15